The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study

Published: October 16, 2015
Category: Bibliography > Papers
Authors: al RS,, avura S,, Earle CC, Goldhar HA, han KK., ien K,, Ko DT, rahn MD,, rezden-Masley C,, rzyzanowska MK,, Tomlinson GA, Trudeau M, Yan AT
Countries: Canada
Language: null
Types: Population Health
Settings: Academic, PCP

J Natl Cancer Inst 108:10.

University of Toronto, Toronto, ON, Canada; St. Michael’s Hospital, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Ontario Institute for Cancer Research, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Toronto Health Economics and Health Assessment, Toronto, ON, Canada; St. Michael’s Hospital, Toronto, ON, Canada; Queens University, Kingston, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; Cancer Care Ontario, Toronto, ON, Canada

BACKGROUND: The late cardiac effect of adjuvant trastuzumab and its potential interaction with anthracycline have not been well-studied on a population level.

METHODS: In this retrospective population-based cohort study, female breast cancer patients in Ontario, diagnosed between 2003 and 2009, were identified by the Ontario Cancer Registry and linked to administrative databases to ascertain demographics, cardiac risk factors, comorbidities, and use of adjuvant trastuzumab and other chemotherapy. Patients with pre-existing heart failure (HF) were excluded. The main endpoint was new diagnosis of HF. Analyses included Kaplan-Meier (KM) survival analysis, multivariable piecewise Cox regression, and competing risk and propensity score analyses. All statistical tests were two-sided.

 RESULTS:Nineteen thousand seventy-four women with breast cancer treated with adjuvant chemotherapy were identified, of whom 3371 (17.7%) also received adjuvant trastuzumab. Anthracycline use was 84.9% overall. After a median follow-up of 5.9 years, patients treated with trastuzumab and chemotherapy were more likely to develop HF than patients on chemotherapy alone (5-year cumulative incidences of 5.2% vs 2.5%; log-rank P < .001). After adjusting for confounders, adjuvant trastuzumab remained independently associated with incident HF in the first 1.5 years (HR = 5.77, 95% CI = 4.38 to 7.62, P .001), but not thereafter (HR = 0.87, 95% CI = 0.57 to 1.33, P = .53). Anthracycline use did not increase the risk of HF with trastuzumab synergistically, neither within (P interaction = .92) nor beyond 1.5 years (P interaction = .23).

CONCLUSION: Adjuvant trastuzumab was associated with increased risk of new incidence of HF in breast cancer survivors during the period of adjuvant treatment but not thereafter. Routine intensive monitoring may not be necessary after completing adjuvant therapy.

PMID: 26476433

Canada,High-Impact Chronic Conditions,Co-morbidity,Medications,Gender,Adult,Age Factors,Antineoplasic Agents/administration & dosage,Breast Neoplasms/pathology,Breast Neoplasms/surgery,Chemotherapy,Adjuvant,Confounding Factors (Epidemiology),Heart Failure/diagnosis,Incidence,Kaplan-Meier Estimate,Middle Aged,Neoplasm Staging,Ontario/epidemiology,Retrospective Studies,Risk Assessment,Risk Factors,Survivors/statistics & numerical data,Time Factors,Trastuzumab/administration & dosage

Please log in/register to access.

Log in/Register

LinkedIn Facebook Twitter

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top